Carecubes, Inc. appears in FDA records as the applicant for a negative pressure isolation chamber intended to create a contained care environment around a standard hospital bed. The supplied collection holds one linked 510(k) record, K260180, with a Substantially Equivalent decision dated October 16, 2026, and the record sample carries the same single entry. That count describes the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. A separate clearance letter in the sources addresses K231256, giving the company two dated submission examples across the material reviewed. [1][5][4]
Documented device and components
The cleared device is named Carecube Negative Pressure Isolation Chamber (1BY) in the K260180 record, where FDA classifies it as a patient isolation chamber in Class II under regulation number 880.5450, product code LGM, with General Hospital as the medical specialty and review panel. The K231256 letter names the same trade device as Carecube Negative Pressure Isolation Chamber and describes the regulation as Patient Care Reverse Isolation Chamber. Carecubes' own instructions for use describe a Model 1BX configuration with an external frame, canopy, airlock pass-through, manometer ports, a footwall entry/exit roll-up door and a sidewall entry/exit. [1][5][8]
Carecubes' product page describes Lean-In Windows, including a middle trunk intended to pass stethoscopes or ultrasound probes and a side window for vitals and day-to-day tasks. The company states the Carecube sets up in 20 minutes on that page, while its home page describes converting a standard hospital bed into an isolation bed in as few as 10 minutes. Those are company-published claims, not independently verified figures. [3][4]
Submission history and regulatory scope
K231256 was received May 1, 2023, and cleared January 3, 2024, according to the FDA clearance letter addressed to Steve Bollinger as Operational Lead at a Monroeville, Pennsylvania address. That letter states the device is substantially equivalent to the CAPSUL Patient Isolation Unit cleared under K052798. The later K260180 record lists a San Francisco, California address, a receipt date of January 21, 2026, a Traditional clearance type, no third-party review and a Summary statement. Filing addresses are correspondence addresses in these records and are not treated here as headquarters. [5][1]
The K260180 database entry records decision code SESE, described as Substantially Equivalent, under the General Hospital advisory committee. The corresponding premarket notification page lists the same Traditional type, no third-party review, no combination product and no authorized predetermined change control plan. [1][2]
Published testing and registration statements
Carecubes states on its product page that the Carecube has undergone testing by third-party services it identifies as Intertek, Mesa 3, Nelson Labs and DDL, and that this testing covers safety, efficacy and compliance with industry standards. The underlying test reports, protocols and results are not included in the public information, so the scope and outcomes of that testing remain unknown here. [3]
A separate Carecubes page states that the Carecube Negative Pressure Isolation Chamber is registered with FDA as a Class II medical device and offers a downloadable establishment registration and device listing letter behind a form. The K260180 openFDA fields list several registration numbers and FEI numbers associated with the record; the company page itself does not enumerate them in the public information. [6][1]
Identity and open questions
Across the FDA records and company pages, the applicant and publisher is Carecubes, Inc.; no parent, subsidiary or brand relationship is verified in the public documents. The instructions for use carry a revision D document number and a limited equipment warranty section, and an earlier revision C of the same document appears in the sources, indicating document revision activity without establishing product changes between them. Commercial availability, customers, pricing and independent clinical performance are not documented in the material reviewed. [8][9][4]

